Dupixent and Cutaneous T-Cell Lymphoma: Legal Help for Those Affected

Have You or a Loved One Been Diagnosed with Cutaneous T-Cell Lymphoma After Taking Dupixent?

Recent investigations by the U.S. Food and Drug Administration (FDA) and multiple observational studies have raised serious concerns about a potential link between the prescription drug Dupixent (dupilumab) and the development or worsening of Cutaneous T-Cell Lymphoma (CTCL)—a rare but aggressive form of non-Hodgkin’s lymphoma that affects the skin.

If you or someone you love took Dupixent and were later diagnosed with CTCL, you may be entitled to financial compensation. Our legal team is currently investigating cases nationwide and offering free consultations to individuals who may have been harmed by this medication. While investigations are ongoing, our legal team is evaluating potential cases.

What Is Dupixent?

Dupixent is an injectable biologic drug manufactured by Sanofi and Regeneron. It is FDA-approved for the treatment of:

• Moderate-to-severe atopic dermatitis (eczema)
• Asthma
• Chronic rhinosinusitis with nasal polyps

While many patients have found relief from Dupixent, reports have surfaced suggesting the drug may be associated with serious long-term risks, including Cutaneous T-Cell Lymphoma.

What Is Cutaneous T-Cell Lymphoma (CTCL)?

CTCL is a rare cancer of the immune system, primarily affecting the skin. Symptoms often include:

• Persistent rashes or eczema-like patches
• Skin thickening or tumors
• Severe itching
• Fatigue or enlarged lymph nodes

CTCL is frequently misdiagnosed as eczema or psoriasis in its early stages, leading to delays in proper diagnosis and treatment.

What’s the Concern with Dupixent and CTCL?

Several case reports and clinical observations have raised red flags that Dupixent may worsen, unmask, or potentially trigger Cutaneous T-Cell Lymphoma, especially in patients treated for long-standing skin conditions. In some instances, patients with misdiagnosed CTCL received Dupixent for presumed eczema—only to later experience disease progression.

In light of these concerns, the FDA is currently reviewing data to determine whether stronger warnings or regulatory action are needed.

Who May Qualify for a Case?

You may be eligible to pursue a legal claim if:

• You were prescribed Dupixent for eczema or another condition
• You were later diagnosed with Cutaneous T-Cell Lymphoma
• Your condition worsened significantly while on the drug

Each case is unique. Our experienced legal team will evaluate your individual circumstances and determine whether you may be entitled to compensation for medical bills, pain and suffering, and other damages.

Why Choose MiglioreLaw?

At Rudolph F.X. Migliore, P.C., we have over 35 years of experience handling complex drug injury cases across the United States. We work closely with a nationwide network of medical experts and co-counsel to ensure that each client receives high-quality representation.

• Free and confidential consultations
• No legal fees unless we win your case
• Personalized attention from a skilled legal team
• Proven results in pharmaceutical injury cases

Contact Us Today to Learn Your Legal Options

If you or a loved one were diagnosed with Cutaneous T-Cell Lymphoma after using Dupixent, don’t wait. Time limits apply to these cases, and early legal intervention can make a critical difference.

📞 Call us now at 631-543-3663
📩 Or submit a free case evaluation through our secure online form.